Portal de Periódicos da CAPES

Somatostatin receptor imaging

2002; Elsevier BV; Volume: 32; Issue: 2 Linguagem: Inglês

10.1053/snuc.2002.31022

1558-4623

Dik J. Kwekkeboom, Eric P. Krenning,

Lung Cancer Research Studies

[111In-DTPA0]octreotide is a radiopharmaceutical with a great potential for the visualization of somatostatin receptor-positive tumors. The overall sensitivity of Somatostatin Receptor Imaging (SRI) to localize neuroendocrine tumors is high. In a number of neuroendocrine tumor types, as well as in Hodgkin's disease, inclusion of SRI in the localization or staging procedure may be very rewarding, either in terms of cost-effectiveness, patient management, or qulity of life. The value of SRI in patients with other tumors, like breast cancer, or in patients with granulomatous diseases, has to be established. The development of Peptide Receptor Radionuclide Therapy (PRRT) is expected to stimulate peptide receptor imaging.